Medipost said Thursday that it hit record sales of 266 vials for Cartistem, a stem-cell treatment for knee cartilage defects in patients with osteoarthritis caused by degenerative or recurrent trauma, in November.
Cartistem is the world’s first allogeneic stem cell drug, which won the marketing license from the Ministry of Food and Drug Safety in January 2012.
The sales volume of Cartistem had consecutively exceeded 200 vials since July, when the company started to sell the product on its own.
The average monthly vial sales for Cartistem was 28 in 2012, 56 in 2013, 80 in 2014, 103 in 2015, 148 in 2016 and as of the end of November this year, the number stands at 195.
Thanks to such growth, Medipost expects that the cumulative injection cases for Cartistem will exceed 7,000 by the end of this year.
“As a result of recent research on joint-related biopharmaceuticals, the company expects synergies within the industry, including the expansion of the total arthritis treatment market,” a company 메디포스트 official said. “The demand for Cartistem is likely to increase in the future as it has proven sustainable effects for cartilage regeneration and pain relief through long-term follow-up clinical trials.”
<© Korea Biomedical Review, All rights reserved.>